Pacira Pharmaceuticals (PCRX) PT Lowered to $82 at Needham & Company, Following Earnings
Needham & Company analyst Serge Belanger lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $82.00 (from $85.00) while maintaining a Buy rating.